Clinical Trials Logo

Clinical Trial Summary

Investigate the effectiveness and safety of pars plans vitrectomy, with internal limiting membrane peeling for cases of myopic traction maculopathy


Clinical Trial Description

Performing pars plana vitrectomy for highly myopic patients with decreased visual acuity is the standard of care for patients with myopic traction. A variety of findings are seen by Optical Coherence Tomography. Epiretinal membranes, retinoschisis, lamellar macular holes, and full thickness macular holes are seen. Undergoing vitrectomy, with or without tamponade, in our center, is retrospectively evaluated. Visual acuity change, as well as improvement of the retinal structure by OCT will be examined. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04278079
Study type Interventional
Source Tanta University
Contact
Status Completed
Phase N/A
Start date January 2015
Completion date February 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05990829 - Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed by Intraoperative OCT (the VIDEO Study): Study Protocol for a Randomized Controlled Trial Phase 4
Recruiting NCT05631054 - Establishment and Validation of a Risk Prediction Model for Long-term Low Vision After Vitrectomy in PDR Patients
Recruiting NCT05728476 - Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema N/A
Recruiting NCT04774146 - Quantification of Silicone Oil Emulsification After Pars Plana Vitrectomy
Not yet recruiting NCT05592912 - Safety and Efficacy of HydroLenz for Vitrectomy-Induced Lens Opacities Phase 1
Completed NCT05013281 - Suprachoroidal Hemorrhage Associated With Pars Plana Vitrectomy
Completed NCT00548197 - Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment Phase 1
Terminated NCT00936520 - SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy Phase 1
Recruiting NCT05248334 - A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy Phase 1